Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Sparsentan · Filspari, RE-021

Small molecule · Antagonist of endothelin type A receptor (EDNRA) and angiotensin II type 1 receptor (AGTR1) · developed by Travere

Approved FDA, Feb 2023
TVTX Developer
4 Registered trials

What is Sparsentan?

Sparsentan is an oral dual antagonist of the endothelin type A receptor and the angiotensin II type 1 receptor. By blocking both receptors, it counters endothelin-1 and angiotensin II effects such as vasoconstriction, podocyte injury and fibrosis. It is studied in immunoglobulin A nephropathy, focal segmental glomerulosclerosis, proteinuria, kidney transplant and hypertension.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Filspari, RE-021, PS-433540
Drug type
Small molecule
Targets
endothelin type A receptor (EDNRA), angiotensin II type 1 receptor (AGTR1)
Mechanism
Antagonist of endothelin type A receptor (EDNRA) and angiotensin II type 1 receptor (AGTR1)
Pathways
endothelin-1 signaling, renin-angiotensin-aldosterone system
Therapy area
Cardiovascular, Renal & urology
Developer
Travere (TVTX)
Also in trials of
LGND
FDA status
Approved as Filspari (February 17, 2023), NDA216403 · FDA label
UNII
9242RO5URM

✅ FDA-approved uses

From the indications section of the FDA label (version of Apr 9, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07219121 Phase 4 Proteinuria Active not recruiting TVTX
NCT01613118 Phase 2 Focal Segmental Glomerulosclerosis Completed TVTX
NCT00522925 Phase 2 Hypertension Completed LGND
NCT05562362 Phase 1 Healthy Subjects Completed TVTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Immunoglobulin A (IgA) NephropathyKidney TransplantProteinuriaFocal Segmental GlomerulosclerosisHealthy SubjectsHypertension

Other drugs acting on EDNRA / AGTR1

More from Travere

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the TVTX page.

Follow TVTX, the company behind Sparsentan

See TVTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

TVTX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.